Actuate Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACTU Nasdaq 2836 actuatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actuate Therapeutics, Inc.

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - Jan 12th, 2026 6:45 am
Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data - Jan 6th, 2026 8:14 am
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - Jan 6th, 2026 6:45 am
Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock? - Dec 24th, 2025 10:00 am
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - Dec 18th, 2025 6:45 am
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - Dec 15th, 2025 6:45 am
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - Nov 28th, 2025 7:55 am
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation - Nov 15th, 2025 5:00 am
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - Sep 22nd, 2025 6:45 am
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option - Sep 11th, 2025 2:01 pm
Sector Update: Health Care Stocks Retreat Late Afternoon - Sep 10th, 2025 1:52 pm
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - Sep 10th, 2025 6:31 am
Actuate Therapeutics Announces Proposed Public Offering of Common Stock - Sep 9th, 2025 2:07 pm
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy - Aug 25th, 2025 8:00 am
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20% - Aug 15th, 2025 4:28 am
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - Aug 6th, 2025 6:45 am
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - Jul 17th, 2025 6:45 am
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial - Jun 24th, 2025 7:15 am
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - Jun 20th, 2025 6:45 am
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Jun 16th, 2025 6:30 am